Venus Remedies receives approval for meropenem in Switzerland

Venus Remedies, through its German subsidiary Venus Pharma GmbH, has received marketing authorisation for generic meropenem 500 mg and 1 g injection in Switzerland. With this approval, Venus Remedies aims to capture 10% share of the meropenem market in Switzerland.
 
The company is planning to launch meropenem, a carbapenem drug of last resort being used in ICU, early next year through its partner Swiss Pharma GmbH to expand its presence in the division. Meropenem, the global annual generic sales of which stood at $1,879 million in 2012, is estimated to grow at a compounded annual growth rate of 7.5 per cent to reach around $2,100 million in 2014-15.
 
Venus Remedies has secured more than 40 marketing authorisations for meropenem across the world in countries such as the UK, France, Germany, Saudi Arabia, Australia, Italy, etc.